| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_42e94091a4fc81b8d0237117707cc7ee |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70521 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2017-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38dba0bde0b124d44b80a9b52dd4ab76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_492691b9fb99d09e6754b59c1662cf79
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_70b0455de9ed0c842eea81e339e2a773
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_749d37b2302617126cd2bf4a86f4a9d9 |
| publicationDate |
2019-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-110072890-A |
| titleOfInvention |
Activatable anti-CTLA-4 antibodies and uses thereof |
| abstract |
Provided herein are activatable anti-human CTLA-4 antibodies comprising: a heavy chain comprising a VH domain and a light chain comprising a masking moiety (MM), a cleavable moiety (CM) and a VL domain. Such activatable anti-human CTLA-4 antibodies have CTLA-4 binding activity in the tumor microenvironment where the masking moiety is removed by proteolytic cleavage of the cleavable moiety by a tumor-specific protease, but exhibit greatly reduced association with tumors. Binding of extra-CTLA-4. In this manner, the activatable anti-human CTLA-4 antibodies of the invention retain anti-tumor activity while reducing side effects associated with extra-tumoral anti-CTLA-4 activity. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021238932-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110498856-A |
| priorityDate |
2016-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |